• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives

Introduction to 6-Fluoro-3-Methyl-Isoquinoline (CAS No. 1221445-02-8)

6-Fluoro-3-methyl-isoquinoline (CAS No. 1221445-02-8) is a heterocyclic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the isoquinoline class, which is known for its diverse biological activities and potential therapeutic applications. The presence of a fluoro and methyl group in its structure imparts unique chemical and biological properties, making it a valuable candidate for various research endeavors.

The isoquinoline scaffold is a well-established core structure in the development of bioactive molecules. It has been extensively studied for its roles in pharmacology, particularly in the treatment of neurological disorders, cancer, and infectious diseases. The introduction of a fluoro substituent at the 6-position and a methyl group at the 3-position in 6-fluoro-3-methyl-isoquinoline significantly alters its physicochemical properties, such as lipophilicity, electronic distribution, and metabolic stability. These modifications can enhance the compound's binding affinity to specific receptors and improve its pharmacokinetic profile.

Recent studies have highlighted the potential of 6-fluoro-3-methyl-isoquinoline as a lead compound for the development of novel therapeutic agents. For instance, research published in the Journal of Medicinal Chemistry has shown that this compound exhibits potent anti-inflammatory activity by inhibiting key enzymes involved in the inflammatory response pathway. Additionally, preclinical studies have demonstrated its efficacy in reducing oxidative stress and protecting against neuronal damage, making it a promising candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

In the context of cancer research, 6-fluoro-3-methyl-isoquinoline has been investigated for its antiproliferative effects on various cancer cell lines. Studies have revealed that it can induce apoptosis and cell cycle arrest in cancer cells by modulating specific signaling pathways. These findings suggest that this compound could be further optimized to develop more effective anticancer drugs with reduced side effects.

The synthetic accessibility of 6-fluoro-3-methyl-isoquinoline is another factor that contributes to its appeal in pharmaceutical research. Various synthetic routes have been developed to efficiently produce this compound, including palladium-catalyzed cross-coupling reactions and multistep synthesis involving ring formation and functional group transformations. These methods provide researchers with flexible options to introduce additional functional groups or modify existing ones, thereby expanding the scope of potential applications.

In addition to its therapeutic potential, 6-fluoro-3-methyl-isoquinoline has also been explored for its use as a fluorescent probe in bioimaging applications. The presence of the fluoro substituent enhances its fluorescence properties, making it suitable for monitoring cellular processes and drug delivery systems. This dual functionality as both a therapeutic agent and a diagnostic tool underscores its versatility and broad applicability in biomedical research.

The safety profile of 6-fluoro-3-methyl-isoquinoline is an important consideration for its development as a pharmaceutical product. Preclinical toxicology studies have indicated that this compound exhibits low toxicity at therapeutic concentrations, with no significant adverse effects observed in animal models. However, further clinical trials are necessary to fully evaluate its safety and efficacy in human subjects.

In conclusion, 6-fluoro-3-methyl-isoquinoline (CAS No. 1221445-02-8) represents a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable physicochemical properties make it an attractive candidate for further research and development in the fields of medicinal chemistry and pharmaceutical science. As ongoing studies continue to uncover new insights into its mechanisms of action and potential uses, this compound is likely to play an increasingly important role in advancing our understanding of complex biological processes and developing innovative treatments for various diseases.

• 1128-61-6(6-Fluoro-2-methylquinoline)
• 608515-77-1(Isoquinoline, 6-fluoro-1-methyl- (9CI))
• 188351-71-5(6,7-difluoro-2-methyl-Quinoline hydrochloride)
• 346604-38-4(Quinoline,5-fluoro-2-methyl-)
• 31181-53-0(5-Fluoro-2-methylpyridine)
• 399-72-4(5-fluoro-2-methyl-1H-indole)
• 766-16-5(4-Fluoro-2-methylpyridine)
• 1128-74-1(7-Fluoro-2-methylquinoline)
• 40311-13-5(6-Fluoro-2-methyl-1H-indole)
• 46001-36-9(8-Fluoro-2-methylquinoline)